Order Article Reprints

Toja-Camba FJ, García-Quintanilla L, Rodríguez-Martinez L, Tomine J, Cajade-Pascual F, Feitosa C, Zarra-Ferro I, Barreiro-De-Acosta M, González-López J, Mondelo-García C, et al. Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies’ Determination against ELISA. Pharmaceutics. 2023; 15(11):2615. https://doi.org/10.3390/pharmaceutics15112615

Toja-Camba, Francisco José, Laura García-Quintanilla, Lorena Rodríguez-Martinez, Julia Tomine, Francisco Cajade-Pascual, Carolina Feitosa, Irene Zarra-Ferro, Manuel Barreiro-De-Acosta, Jaime González-López, Cristina Mondelo-García, and et al. 2023. "Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies’ Determination against ELISA" Pharmaceutics 15, no. 11: 2615. https://doi.org/10.3390/pharmaceutics15112615

Toja-Camba, F. J., García-Quintanilla, L., Rodríguez-Martinez, L., Tomine, J., Cajade-Pascual, F., Feitosa, C., Zarra-Ferro, I., Barreiro-De-Acosta, M., González-López, J., Mondelo-García, C., & Fernández-Ferreiro, A. (2023). Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies’ Determination against ELISA. Pharmaceutics, 15(11), 2615. https://doi.org/10.3390/pharmaceutics15112615